JP2025041768A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025041768A5 JP2025041768A5 JP2024225122A JP2024225122A JP2025041768A5 JP 2025041768 A5 JP2025041768 A5 JP 2025041768A5 JP 2024225122 A JP2024225122 A JP 2024225122A JP 2024225122 A JP2024225122 A JP 2024225122A JP 2025041768 A5 JP2025041768 A5 JP 2025041768A5
- Authority
- JP
- Japan
- Prior art keywords
- patients
- cscc
- study
- antibody
- regn2810
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962811827P | 2019-02-28 | 2019-02-28 | |
| US62/811,827 | 2019-02-28 | ||
| JP2021550167A JP2022521800A (ja) | 2019-02-28 | 2020-02-27 | 皮膚がんを治療するためのｐｄ－１阻害剤の投与 |
| PCT/US2020/020018 WO2020176699A1 (en) | 2019-02-28 | 2020-02-27 | Administration of pd-1 inhibitors for treating skin cancer |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021550167A Division JP2022521800A (ja) | 2019-02-28 | 2020-02-27 | 皮膚がんを治療するためのｐｄ－１阻害剤の投与 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025041768A JP2025041768A (ja) | 2025-03-26 |
| JP2025041768A5 true JP2025041768A5 (https=) | 2025-06-20 |
Family
ID=70057261
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021550167A Pending JP2022521800A (ja) | 2019-02-28 | 2020-02-27 | 皮膚がんを治療するためのｐｄ－１阻害剤の投与 |
| JP2024225122A Pending JP2025041768A (ja) | 2019-02-28 | 2024-12-20 | 皮膚がんを治療するためのｐｄ－１阻害剤の投与 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021550167A Pending JP2022521800A (ja) | 2019-02-28 | 2020-02-27 | 皮膚がんを治療するためのｐｄ－１阻害剤の投与 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220259313A1 (https=) |
| EP (1) | EP3930848A1 (https=) |
| JP (2) | JP2022521800A (https=) |
| KR (1) | KR20210134690A (https=) |
| CN (1) | CN113490529A (https=) |
| AU (1) | AU2020228296B2 (https=) |
| CA (1) | CA3137361A1 (https=) |
| IL (1) | IL285050A (https=) |
| MA (1) | MA55084A (https=) |
| MX (1) | MX2021010228A (https=) |
| SG (1) | SG11202108089SA (https=) |
| WO (1) | WO2020176699A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| LT3394103T (lt) | 2015-12-22 | 2023-09-11 | Regeneron Pharmaceuticals, Inc. | Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti |
| WO2020118208A1 (en) | 2018-12-07 | 2020-06-11 | Arizona Board Of Regents On Behalf Of The University Of Arizona | A method of determining risk for skin cancer development and skin cancer therapeutic prevention by measuring pd-1/pd-l1 signaling pathway members |
| WO2022173931A1 (en) * | 2021-02-11 | 2022-08-18 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer by administering a neoadjuvant pd-1 inhibitor |
| WO2024186917A2 (en) * | 2023-03-06 | 2024-09-12 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions for pd-l1 inhibition and methods of use thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| CA2840018C (en) | 2011-07-24 | 2019-07-16 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| KR20220084444A (ko) | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| RU2689760C2 (ru) | 2012-05-31 | 2019-05-30 | Дженентек, Инк. | Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| KR102476226B1 (ko) | 2014-08-05 | 2022-12-12 | 아폴로믹스 인코포레이티드 | 항-pd-l1 항체 |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| ES2986067T3 (es) * | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| LT3394103T (lt) * | 2015-12-22 | 2023-09-11 | Regeneron Pharmaceuticals, Inc. | Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti |
| SG11201808626WA (en) | 2016-04-07 | 2018-10-30 | Chemocentryx Inc | Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors |
| TWI910495B (zh) * | 2016-05-13 | 2026-01-01 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| MA47604A (fr) * | 2017-02-21 | 2020-01-01 | Regeneron Pharma | Anticorps anti-pd-1 pour le traitement du cancer du poumon |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| CN111201035A (zh) * | 2017-06-19 | 2020-05-26 | 梅迪塞纳医疗股份有限公司 | Il-2超激动剂、激动剂及其融合体的用途和方法 |
-
2020
- 2020-02-27 MA MA055084A patent/MA55084A/fr unknown
- 2020-02-27 CN CN202080017060.8A patent/CN113490529A/zh active Pending
- 2020-02-27 AU AU2020228296A patent/AU2020228296B2/en active Active
- 2020-02-27 EP EP20715554.0A patent/EP3930848A1/en active Pending
- 2020-02-27 SG SG11202108089SA patent/SG11202108089SA/en unknown
- 2020-02-27 WO PCT/US2020/020018 patent/WO2020176699A1/en not_active Ceased
- 2020-02-27 MX MX2021010228A patent/MX2021010228A/es unknown
- 2020-02-27 JP JP2021550167A patent/JP2022521800A/ja active Pending
- 2020-02-27 US US17/433,003 patent/US20220259313A1/en active Pending
- 2020-02-27 KR KR1020217030808A patent/KR20210134690A/ko active Pending
- 2020-02-27 CA CA3137361A patent/CA3137361A1/en active Pending
-
2021
- 2021-07-22 IL IL285050A patent/IL285050A/en unknown
-
2024
- 2024-12-20 JP JP2024225122A patent/JP2025041768A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022078265A (ja) | 肺癌の処置のための抗ｐｄ－１抗体 | |
| AU2020228296B2 (en) | Administration of PD-1 inhibitors for treating skin cancer | |
| JP2025041768A5 (https=) | ||
| JP2022532490A (ja) | 癌の治療における有効性の増強のためのｐｄ－１阻害剤とｌａｇ－３阻害剤の組み合わせ | |
| TW201806616A (zh) | 抗－ｐｄ－１抗體與輻射治療癌症之組合 | |
| US20260042841A1 (en) | Intralesional administration of pd-1 inhibitors for treating skin cancer | |
| US20250326846A1 (en) | Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor | |
| JP2026508608A (ja) | メラノーマの治療における有効性の増強のためのｐｄ－１阻害剤及びｌａｇ－３阻害剤の組み合わせ | |
| CN117042795A (zh) | 通过施用pd-1抑制剂治疗免疫抑制或免疫受损患者的癌症的方法 | |
| JP2021107384A (ja) | 部位特異的ｈｅｒ２抗体薬物コンジュゲートを用いた処置 | |
| HK40112560A (en) | Intralesional administration of pd-1 inhibitors for treating skin cancer | |
| JP2024507866A (ja) | Ｐｄ－１阻害剤を投与することにより肺がんを処置する方法 | |
| HK40057287B (en) | Intralesional administration of pd-1 inhibitors for treating skin cancer | |
| HK40057287A (en) | Intralesional administration of pd-1 inhibitors for treating skin cancer | |
| EP4701650A2 (en) | Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor | |
| CN116887863A (zh) | 通过施用pd-1抑制剂治疗肺癌的方法 |